Zentiva Pharma UK Limited
Registered name: ZENTIVA PHARMA UK LIMITED
Zentiva Pharma UK Limited made £119m revenue and a £791k loss in the year to 31 Dec 2025.
Zentiva Pharma UK Limited’s revenue fell 3% to £119m in the year to 31 Dec 2025, with a loss of £791k and 51 employees. The company is classified under “wholesale of pharmaceutical goods” and is based in London; we hold 2 years of its filed accounts.
- Status
- Active
- Location
- London, London
- Age
- 39 yrs · since 1987
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|
| Disclosure | Full P&L | Full P&L |
| Profit & loss | ||
| Revenue (turnover) | £123m | £119m |
| Cost of sales | £104m | £102m |
| Gross profit | £19.9m | £17.8m |
| Operating profit | £3.1m | £2.8m |
| Profit before tax | −£738k | £753k |
| Profit after tax | −£2.2m | −£791k |
| Profit (best available) | −£2.2m | −£791k |
| Staff costs | £5.4m | £7.2m |
| Employees (average) | 52 | 51 |
| Ratios | ||
| Profit margin | −1.8% | −0.7% |
| Gross margin | 16.2% | 14.9% |
| Revenue per employee | £2.4m | £2.3m |
| Profit per employee | −£42.1k | −£15.5k |
| Growth (year on year) | ||
| Revenue growth | — | ▼3.3% |
| Headcount growth | — | ▼1.9% |
| Balance sheet — indirect signals, not revenue | ||
| Net assets | £8.3m | £7.6m |
| Fixed assets | £10.8m | £7.8m |
| Current assets | £82.7m | £84m |
| Debtors | £6.9m | £4.9m |
| Deferred income | £10.3m | £10.9m |
| Source | FullAccounts · bulk data Jun 2026 | FullAccounts · bulk data Jun 2026 |
How the business works
- Profit margin
- −0.7%
- Profit ÷ revenue.
- Gross margin
- 14.9%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £2.3m
- Revenue ÷ average employees.
- Profit per employee
- −£15.5k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 6.6%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 9.1%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 4.1%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼9%
- Now £7.6m
- Cash at bank
- —
- Now —
- Headcount
- ▼2%
- Now 51
- Deferred income
- ▲6%
- Now £10.9m
- Fixed assets
- ▼28%
- Now £7.8m
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Similar profitable businesses
- Aspire Pharma LimitedGodalming · Wholesale of pharmaceutical goods
- Revenue
- £118m
- Profit
- £21.8m
- Staff
- 114
- Steris Solutions LimitedBasingstoke · Wholesale of pharmaceutical goods
- Revenue
- £111m
- Profit
- £4m
- Staff
- 258
- Astute Healthcare LimitedHitchin · Wholesale of pharmaceutical goods
- Revenue
- £130m
- Profit
- £1.9m
- Staff
- 62
- Rayburn Trading Company LimitedSalford · Wholesale of pharmaceutical goods
- Revenue
- £98.5m
- Profit
- £2.3m
- Staff
- 188
- Celltrion Healthcare United Kingdom LimitedUxbridge · Wholesale of pharmaceutical goods
- Revenue
- £156m
- Profit
- £3.8m
- Staff
- 32
- C. S. T. Pharma LimitedWalsall · Wholesale of pharmaceutical goods
- Revenue
- £91.3m
- Profit
- £1.7m
- Staff
- 115
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025 (profit −£791k), from the Companies House accounts bulk data published Jun 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.